Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.70 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.70 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.70 |
| ▸ | PGR | P06401 | 1/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.70 |
| ▸ | HTR2B | P41595 | 1/20 | 0.70 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.70 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GABRP | O00591 | 2/20 | 0.35 |
| ▸ | GABRD | O14764 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20381085 | 1.00 | CACNA2D1 (0.70) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL5917733 | 1.00 | CACNA2D1 (0.70) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL8227 | 0.83 | CACNA2D1 (1.00) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL27754092 | 0.83 | CACNA2D1 (1.00) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL1561104 | 0.83 | CACNA2D1 (1.00) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL2370227 | 0.83 | CACNA2D1 (1.00) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL15497 | 0.83 | CACNA2D1 (1.00) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL263450 | 0.83 | CACNA2D1 (1.00) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL5187943 | 0.82 | CACNA2D1 (0.48) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4412290 | 0.82 | CACNA2D1 (0.74) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4681116-B2 | — | — | 2011-05-11 | — | — | JP | claimed |
| JP-3884486-B2 | — | — | 2007-02-21 | — | — | JP | claimed |
| EP-1549302-A1 | GASTROINTESTINAL COMPOSITIONS COMPRISING GABA DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-07-06 | — | — | EP | claimed |
| EP-1515709-A2 | USE OF AN ALPHA2DELTA LIGAND SUCH AS GABAPENTIN OR PREGABALIN FOR TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER | Warner-Lambert Company LLC (US) | 2005-03-23 | — | — | EP | claimed |
| WO-2004006901-A1 | GASTROINTESTINAL COMPOSITIONS COMPRISING GABA DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | claimed |
| WO-2004002462-A2 | USE OF AN ALPHA2DELTA LIGAND SUCH AS GABAPENTIN OR PREGABALIN FOR TREATING TTENTION DEFICIT HYPERACTIVITY DISORDER | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-08 | — | — | WO | claimed |
| JP-2002506449-A | — | — | 2002-02-26 | — | — | JP | claimed |
| EP-1009399-A1 | GABA ANALOGS TO PREVENT AND TREAT GASTROINTESTINAL DAMAGE | WARNER-LAMBERT COMPANY LLC (US) | 2000-06-21 | — | — | EP | claimed |
| EP-0994704-A1 | USE OF GABA ANALOGS SUCH AS GABAPENTIN IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING INFLAMMATORY DISEASES | WARNER-LAMBERT COMPANY (US) | 2000-04-26 | — | — | EP | claimed |
| WO-1999008671-A1 | GABA ANALOGS TO PREVENT AND TREAT GASTROINTESTINAL DAMAGE | WARNER-LAMBERT COMPANY (US) | 1999-02-25 | — | — | WO | claimed |
| WO-1999008670-A1 | GABA ANALOGS TO PREVENT AND TREAT GASTROINTESTINAL DAMAGE | GUGLIETTA, ANTONIO | 1999-02-25 | — | — | WO | claimed |
| WO-1998058641-A1 | USE OF GABA ANALOGS SUCH AS GABAPENTIN IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING INFLAMMATORY DISEASES | WARNER-LAMBERT COMPANY (US) | 1998-12-30 | — | — | WO | claimed |
| CN-116322664-A | Method of neuroprotection and uses thereof | 欧库罗治疗有限责任公司 | 2023-06-23 | — | — | CN | disclosed |
| US-9422230-B2 | Process for the preparation of an anticonvulsant agent pregabalin hydrochloride | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-08-23 | — | — | US | disclosed |
| US-20160122289-A1 | PROCESS FOR THE PREPARATION OF AN ANTICONVULSANT AGENT PREGABALIN HYDROCHLORIDE | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-05-05 | — | — | US | disclosed |
| EP-2405754-A1 | MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS OF BUPRENORPHINE | Theraquest Biosciences, Inc. (US) | 2012-01-18 | — | — | EP | disclosed |
| WO-2000053225-A1 | ANALGESIC COMPOSITIONS COMPRISING ANTI-EPILEPTIC COMPOUNDS AND METHODS OF USING SAME | WARNER-LAMBERT COMPANY (US) | 2000-09-14 | — | — | WO | disclosed |
| EP-1009399-A1 | GABA ANALOGS TO PREVENT AND TREAT GASTROINTESTINAL DAMAGE | WARNER-LAMBERT COMPANY LLC (US) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999008671-A1 | GABA ANALOGS TO PREVENT AND TREAT GASTROINTESTINAL DAMAGE | WARNER-LAMBERT COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |
| WO-1999008670-A1 | GABA ANALOGS TO PREVENT AND TREAT GASTROINTESTINAL DAMAGE | GUGLIETTA, ANTONIO | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122289-A1 | PROCESS FOR THE PREPARATION OF AN ANTICONVULSANT AGENT PREGABALIN HYDROCHLORIDE | GABRE, GABRG1, GABRB2 | CACNA2D1 95/4885CACNB3 129/4885CACNA1C 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.